Company Description
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.
The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity.
It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease.
Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
| Country | United States |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Sergio Traversa |
Contact Details
Address: 2222 Ponce de Leon Blvd., Floor 3 Coral Gables, Florida 33134 United States | |
| Phone | 786 629 1376 |
| Website | relmada.com |
Stock Details
| Ticker Symbol | RLMD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001553643 |
| CUSIP Number | 75955J402 |
| ISIN Number | US75955J4022 |
| Employer ID | 45-5401931 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sergio Traversa M.B.A., Pharm.D. | Chief Executive Officer and Director |
| Maged S. Shenouda M.B.A., R.Ph. | Chief Financial Officer |
| Paul E. Kelly M.B.A. | Chief Operating Officer and Director |
| Charles S. Ence CPA, M.B.A. | Chief Accounting and Compliance Officer |
| Gina DiGuglielmo | Vice President and Head of Clinical Operations |
| Dr. Andrew Cutler | Senior Clinical Development Advisor |
| Dr. Richard M. Mangano Ph.D. | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2025 | 10-Q | Quarterly Report |
| May 12, 2025 | 8-K | Current Report |
| May 1, 2025 | SCHEDULE 13G | Filing |
| Apr 28, 2025 | 424B5 | Filing |
| Apr 28, 2025 | 8-K | Current Report |
| Apr 11, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 11, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 27, 2025 | 8-K | Current Report |
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 26, 2025 | 8-K | Current Report |